Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
LP-118 by Newave Pharmaceutical for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
LP-118 is under clinical development by Newave Pharmaceutical and currently in Phase I for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute...
LP-118 by Newave Pharmaceutical for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
LP-118 is under clinical development by Newave Pharmaceutical and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According...
LP-118 by Newave Pharmaceutical for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
LP-118 is under clinical development by Newave Pharmaceutical and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). According...
LP-118 by Newave Pharmaceutical for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma): Likelihood of Approval
LP-118 is under clinical development by Newave Pharmaceutical and currently in Phase I for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma). According to...
LP-118 by Newave Pharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
LP-118 is under clinical development by Newave Pharmaceutical and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
LP-118 by Newave Pharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval
LP-118 is under clinical development by Newave Pharmaceutical and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...